{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115033","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.091113+00:00","generated_at":"2026-05-30T03:53:46.690869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zura Bio Q3 net loss $22.9M; cash $188.2M; Phase 2 trials on track for SSc and HS","bullets":["Net loss of $22.9M ($0.26 per share) vs $8.3M ($0.18) in Q3 2023; G&A up $7.1M on one-time stock comp and warrant exchange.","Cash, cash equivalents and investments $188.2M as of Sep 30, 2024, up from $99.8M at Dec 31, 2023; expected to fund operations through 2027.","Phase 2 trial of tibulizumab for systemic sclerosis expected to initiate Q4 2024; Orphan Drug Designation request submitted to FDA.","Phase 2 trial of tibulizumab for hidradenitis suppurativa anticipated to start Q2 2025; IND submission expected Q1 2025.","Completed warrant exchange in August 2024 and established ATM program for financial flexibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115033","json":"https://secwatch.observer/filing/0001104659-24-115033.json","markdown":"https://secwatch.observer/filing/0001104659-24-115033.md","text":"https://secwatch.observer/filing/0001104659-24-115033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924115033/0001104659-24-115033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924115033/tm2427543d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:53:46.690869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}